Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 231.33M |
| Revenue (ttm) | 44.64M |
| Net Income (ttm) | -9.74M |
| Shares Out | 34.48M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | 54.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,068 |
| Open | 6.85 |
| Previous Close | 6.85 |
| Day's Range | 6.66 - 6.93 |
| 52-Week Range | 5.58 - 9.92 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+116.1%) |
| Earnings Date | May 12, 2026 |
About FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of oto... [Read more]
Financial Performance
In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$9.74 million, 2134.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price target is $14.5, which is an increase of 116.10% from the latest price.
News
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced th...
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigatio...
Fennec Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 sales and robust AYA growth drove a 50% revenue increase, supported by expanded teams, new clinical evidence, and a strengthened balance sheet. U.S. exclusivity for PEDMARK is secured through 2033, with major European launches and further growth expected in 2026.
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75%...
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Me...
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on Dec...
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
Fennec Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
PEDMARK, the only FDA-approved therapy for cisplatin-induced ototoxicity in pediatric and AYA patients, is expanding its market reach with strong sales growth, broad payer coverage, and new data supporting efficacy and safety. European and Japanese launches are underway, with ongoing efforts to expand indications and awareness.
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates o...
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the...
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the...
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...
Fennec Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
PEDMARK achieved record sales and three consecutive quarters of growth, driven by expanded leadership, new global partnerships, and broadened market access, especially in the AYA segment. Strong IP, reimbursement success, and robust patient support position the company for continued momentum.
Fennec Pharmaceuticals Earnings Call Transcript: Q2 2025
Q2 2025 net product sales grew 33% year-over-year to $9.7M, marking the third consecutive quarter of sequential growth. PEDMARK adoption expanded with 14 new accounts, and EU commercialization via Norgine is gaining traction. Cash OpEx is expected to decrease in H2 2025.
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Pra...
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...
Fennec Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
PEDMARK’s unique FDA-approved position in preventing cisplatin-induced hearing loss is driving growth, with recent expansion into the AYA segment and strong international partnerships. Financials are approaching break-even, and further milestones in Europe and Japan are expected to accelerate value.
Fennec Pharmaceuticals Earnings Call Transcript: Q1 2025
Q1 2025 saw 18% year-over-year sales growth, driven by strategic focus, AYA segment expansion, and international launches. Cash burn was $4M, with operating expenses expected to remain stable for the year. PEDMARK adoption is rising in both academic and community settings.
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...